Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CCND1 | P24385 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18856959 | 0.85 | HTR2C (0.59) | SCN9AHTR2AHTR2CCDK4CCND1 | |
| SCHEMBL17886150 | 0.81 | SCN9A (0.44) | SCN9AHTR2AHTR2CGRM2HTR1D | |
| SCHEMBL24418057 | 0.80 | EGFR (0.50) | SCN9AHTR2AHTR2CGRM2HTR1D | |
| SCHEMBL14790349 | 0.80 | SCN9A (0.47) | SCN9AHTR2AHTR2CGRM2HTR1D | |
| SCHEMBL18856954 | 0.76 | HTR2C (0.56) | SCN9AHTR2AHTR2CCDK4CCND1 | |
| SCHEMBL18856949 | 0.75 | HTR2A (0.55) | SCN9AHTR2AHTR2CCDK4CCND1 | |
| SCHEMBL9231907 | 0.74 | HTR2A (0.54) | SCN9AHTR2AHTR2CCDK4CCND1 | |
| SCHEMBL17676473 | 0.74 | HTR2A (0.58) | HTR2AHTR2CCDK4CCND1EGFR | |
| SCHEMBL17867540 | 0.74 | GRIN2B (0.35) | SCN9AHTR2AHTR2CGRM2CDK4 | |
| SCHEMBL14061899 | 0.72 | HTR2A (0.59) | HTR2AHTR2CCDK4CCND1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701904-B2 | Optically isotropic liquid crystal medium and optical device | JNC CORPORATION (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9701904-B2 | Optically isotropic liquid crystal medium and optical device | JNC CORPORATION (JP) | 2017-07-11 | — | — | US | disclosed |
| US-20160186060-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL DEVICE | JNC CORPORATION (JP) | 2016-06-30 | — | — | US | disclosed |
| US-20160186060-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL DEVICE | JNC CORPORATION (JP) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160186060-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL DEVICE | CNOT1, SCO2, OCIAD1 | SCN9A 3095/4885HTR2A 2423/4885HTR2C 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.